Professor Andrew Briggs

BSc (Hons) MSc DPhil


15-17 Tavistock Place
United Kingdom

Professor of Health Economics at the London School of Hygiene & Tropical Medicine, I  previously held the William R Lindsay Chair in Health Economics at the University of Glasgow. Following a sabbatical at Memorial Sloan Kettering Cancer Center, New York in 2016/17, I remain a Visiting Investigator, collaborating with Dr Peter Bach on value frameworks for oncology medications.

I have  co-authored two textbooks, one published by OUP entitled Decision Modelling for Health Economic Evaluation, and another published by Wiley entitled Statistical Methods for Cost-Effectiveness Analysis.

A link to my GooGle Scholar page:


Department of Health Services Research and Policy
Faculty of Public Health and Policy


Centre for Evaluation
Centre for Statistical Methodology


My main methodological focus of research has been health economic evaluation, particularly statistical methods for cost-effectiveness analysis.  This includes statistical methods for estimation of parameters for cost-effectiveness models as well as statistical analysis of cost-effectiveness alongside clinical trials.  I have a more general interest in epidemiological methods, in particular the use of prognostic scoring methods for predicting health outcomes and the relationship with heterogeneity in cost-effectiveness analysis.

Research Area
Decision analysis
Economic evaluation
Randomised controlled trials
Health economics
United Kingdom
United States of America
South Africa
European Union
North America
Sub-Saharan Africa (all income levels)

Selected Publications

Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19.
Briggs AH; Goldstein DA; Kirwin E; Meacock R; Pandya A; Vanness DJ; Wisløff T
Health economics
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review.
Cooper JT; Lloyd A; Sanchez JJG; Sörstadius E; Briggs A; McFarlane P
Health and quality of life outcomes
Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.
Hu Y; Briggs A; Marchetti MA; Ariyan CE; Coit DG; Bartlett EK
Journal of the American College of Surgeons
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortés J; Ramsey SD; Briggs A; Hu P; Karantza V; Aktan G
Cancer research
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
Italiano A; Nanda S; Briggs A; Garcia-Foncillas J; Lassen U; Vassal G; Kummar S; van Tilburg CM; Hong DS; Laetsch TW
Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial.
Robles-Zurita JA; Briggs A; Rana D; Quayyum Z; Oldroyd KG; Zeymer U; Desch S; de Waha-Thiele S; Thiele H
The European journal of health economics : HEPAC : health economics in prevention and care
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
See more Publications